225 related articles for article (PubMed ID: 27332628)
1. Increased Frequency of Encopresis in a Child Diagnosed With Attention Deficit/Hyperactivity Disorder and Encopresis After Atomoxetine Use: A Case Report.
Yektaş Ç; Cansiz MA; Tufan AE
Clin Neuropharmacol; 2016; 39(4):212-3. PubMed ID: 27332628
[TBL] [Abstract][Full Text] [Related]
2. [Atomoxetine Treatment For Encopresis In A Child With Attention Deficit Hyperactivity Disorder].
Bozkurt H; Şahin S
Turk Psikiyatri Derg; 2016; 27(2):0. PubMed ID: 27482753
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Atomoxetine in the Treatment of Children With Encopresis.
Türkoğlu S; Bilgiç A; Uzun N
J Clin Psychopharmacol; 2015 Oct; 35(5):622-3. PubMed ID: 26110671
[No Abstract] [Full Text] [Related]
4. Atomoxetine for encopresis in 2 children with attention-deficit/hyperactivity disorder.
Hergüner S; Hergüner A
J Clin Psychopharmacol; 2012 Apr; 32(2):302-3. PubMed ID: 22388168
[No Abstract] [Full Text] [Related]
5. The Effect of Atomoxetin Use in the Treatment of Attention-Deficit/Hyperactivity Disorder on the Symptoms of Restless Legs Syndrome: A Case Report.
Baykal S; Karakurt MN
Clin Neuropharmacol; 2017; 40(2):93-94. PubMed ID: 28195837
[TBL] [Abstract][Full Text] [Related]
6. Skin Picking Successfully Treated With Atomoxetine in Comorbid Skin Picking and Attention-Deficit/Hyperactivity Disorder: A Case Report.
Yurteri N; Sarıgedik E
Clin Neuropharmacol; 2020; 43(4):114-115. PubMed ID: 32541332
[TBL] [Abstract][Full Text] [Related]
7. Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis.
Patra S; Nebhinani N; Viswanathan A; Kirubakaran R
Autism Res; 2019 Apr; 12(4):542-552. PubMed ID: 30653855
[TBL] [Abstract][Full Text] [Related]
8. Increased prefrontal hemodynamic change after atomoxetine administration in pediatric attention-deficit/hyperactivity disorder as measured by near-infrared spectroscopy.
Ota T; Iida J; Nakanishi Y; Sawada S; Matsuura H; Yamamuro K; Ueda S; Uratani M; Kishimoto N; Negoro H; Kishimoto T
Psychiatry Clin Neurosci; 2015 Mar; 69(3):161-70. PubMed ID: 25359429
[TBL] [Abstract][Full Text] [Related]
9. No evidence for predictors of response to atomoxetine treatment of attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder.
Harfterkamp M; van der Meer D; van der Loo-Neus G; Buitelaar JK; Minderaa RB; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2015 May; 25(4):372-5. PubMed ID: 25919900
[No Abstract] [Full Text] [Related]
10. Atomoxetine in Attention-Deficit/Hyperactivity Disorder in Children With and Without Comorbid Mood Disorders.
Shaker NM; Osama Y; Barakat DH; Abdelgawad AA; Abdel Aziz K; Aly El-Gabry D
J Child Adolesc Psychopharmacol; 2021 Jun; 31(5):332-341. PubMed ID: 34143680
[No Abstract] [Full Text] [Related]
11. Atomoxetine in the Treatment of Adolescent With Trichotillomania and Attention-Deficit/Hyperactivity Disorder.
Türkoğlu S; Çetin FH
Clin Neuropharmacol; 2018; 41(2):84-85. PubMed ID: 29533364
[No Abstract] [Full Text] [Related]
12. Effect of Atomoxetine on the Cognitive Functions in Treatment of Attention Deficit Hyperactivity Disorder in Children with Congenital Hypothyroidism: A Pilot Study.
Yang R; Gao W; Li R; Zhao Z
Int J Neuropsychopharmacol; 2015 Apr; 18(8):. PubMed ID: 25896257
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder.
Shang CY; Yan CG; Lin HY; Tseng WY; Castellanos FX; Gau SS
Psychol Med; 2016 Nov; 46(15):3173-3185. PubMed ID: 27574878
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of atomoxetine for symptoms of attention-deficit/hyperactivity disorder in children with a history of child abuse.
Sugimoto A; Suzuki Y; Endo T; Matsumoto K; Sugiyama T; Someya T
J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):269-71. PubMed ID: 25885013
[TBL] [Abstract][Full Text] [Related]
15. [Atomoxetine for treatment of children and adolescents with ADHD].
Resen K; Pagsberg AK; Jörgens G
Ugeskr Laeger; 2014 Mar; 176(10A):. PubMed ID: 25350704
[TBL] [Abstract][Full Text] [Related]
16. Atomoxetine ameliorates nocturnal enuresis with subclinical attention-deficit/hyperactivity disorder.
Ohtomo Y
Pediatr Int; 2017 Feb; 59(2):181-184. PubMed ID: 27501068
[TBL] [Abstract][Full Text] [Related]
17. Atomoxetine Use in Attention-Deficit/Hyperactivity Disorder and Comorbid Tic Disorder in Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections.
Demirkaya SK; Demirkaya M; Yusufoğlu C; Akın E
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):104-105. PubMed ID: 27315236
[TBL] [Abstract][Full Text] [Related]
18. Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study.
Chou TL; Chia S; Shang CY; Gau SS
Eur Neuropsychopharmacol; 2015 Dec; 25(12):2300-10. PubMed ID: 26409297
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder.
Chang K; Nayar D; Howe M; Rana M
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):547-51. PubMed ID: 19877979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
